MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Net Debt · Q3 FY2026 · quarter ended Sep 2026
Net debt remains negative
Q3 FY2026 net debt was -$158.4M, compared with -$222.5M a year earlier.
Context
- Net debt amounted to 31.6% of total assets at the end of Q3 FY2026, down 24.0 pp from a year earlier.
- Net debt grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +28.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (74.69M) USD
- Year-over-year change
- -51.9%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.69M) | -51.9% |
| FY2024 | 2024-12-31 | (49.18M) | -62.9% |
| FY2023 | 2023-12-31 | (30.2M) | -27.2% |
| FY2022 | 2022-12-31 | (23.75M) | — |
Net Debt vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +28.8% is the 2nd highest of 8, against a peer median of -55.5%.
- Net debt amounts to 31.6% of total assets for MBX, versus a peer median of 18.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$12.44M USD | +83.2% | — | 4.6% | |
| Sep 2026 | -$36.47M USD | +23.9% | — | 8.2% | |
| Mar 2026 | -$43.45M USD | -55.5% | — | 93.7% | |
| Mar 2026 | -$61.75M USD | -30.0% | — | 18.4% | |
| Mar 2026 | -$74.42M USD | -135.4% | — | 19.0% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | -$120.09M USD | — | — | 9.9% |
| Jun 2026 | -$121.66M USD | -268.7% | — | 23.3% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | -$158.4M USD | +28.8% | — | 31.6% |
| Sep 2026 | -€516.56M EUR | -288.1% | +13.9% | 21.3% | |
| Peer median (excluding MBX) | — | -55.5% | +13.9% | 18.7% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.